Skip to main content
VCELVericel CorporationHold6.3·$40.10-0.91%

Vericel (VCEL) Q2 2026 earnings — TrendMatrix coverage

BEAT+250.0% vs estimateEPS $0.04 vs -$0.03 estCurrent verdict Hold 6.3/10

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
$0.04
Estimate
-$0.03
Surprise
+250.0%
Revenue (period 2026-06-30)
$77.5M
Score today
6.3/10

Revenue source: xbrl.

Report record · Q2 2026

How the report landed

Vericel (VCEL) beat the -$0.03 estimate with diluted EPS of $0.04 — a large 250.0% upside surprise.

Current read · as of 2026-09-04

Where TrendMatrix's rating stands now

TrendMatrix currently rates VCEL Hold at 6.3/10; no pre/post engine snapshot brackets this report.

4 of the last 4 quarters beat the estimate; this quarter's +250.0% surprise compares with a +285.3% four-quarter average. Next scheduled report: 2026-11-05.

What supports the rating

  • Sector modifier (Healthcare): +0.5
  • Strong earnings beat streak (4/4)

What argues against it

  • Concentration risk — Supplier: Matricel GmbH
  • Concentration risk — Supplier: MediWound
  • Value-trap signals (2/5): Margin compression (op margin 0.6%), Material insider selling (7 sells, 0.10% of cap)

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$40.10
Price target
$52.70
Stop
$38.16
Upside to target
+31.4%
Reward-to-risk
4.4:1

The stock trades at 86.1× trailing but 47.8× forward earnings — consensus estimates already build in a substantial earnings recovery.

Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.

Healthcare context

VCEL at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Biotechnology
Market cap
$2.07B
P/E (fwd)
47.8
P/E (ttm)
86.1
52-week range
$28.95$49.32
Off 52-week high
18.7%
RSI (14)
32
Volume vs avg
0.35×
Score today
6.3/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks VCEL Earnings Q2 2026 earnings